Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CUE – Cue Biopharma Inc

CUE — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

2.34

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

EPS Last/This Y

-0.3

EPS This/Next Y

-0.02

Price

0.19

Target Price

4

Analyst Recom

1

Performance Q

-50.81

Upside

-2,221.1%

Beta

1.58

Ticker: CUE




16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09CUE0.3050.144.001143
2026-03-10CUE0.31010.110.401113
2026-03-11CUE0.320.11999.991118
2026-03-12CUE0.30430.124.001120
2026-03-13CUE0.30420.124.001120
2026-03-17CUE0.27070.127.001132
2026-03-18CUE0.26180.130.001150
2026-03-20CUE0.25830.14999.991156
2026-03-25CUE0.26040.130.321171
2026-03-26CUE0.24630.140.001218
2026-03-27CUE0.23090.140.001218
2026-03-30CUE0.22920.140.001218
2026-03-31CUE0.22410.140.001221
2026-04-01CUE0.20180.140.001221
2026-04-06CUE0.17990.142.671226
2026-04-07CUE0.18640.140.001235
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09CUE0.30- - -0.41
2026-03-10CUE0.31- - -0.41
2026-03-11CUE0.32- - -0.41
2026-03-12CUE0.30- - -0.41
2026-03-13CUE0.27- - -0.41
2026-03-17CUE0.27- - -0.41
2026-03-18CUE0.26- - -0.41
2026-03-19CUE0.26- - -0.41
2026-03-20CUE0.26- - -0.58
2026-03-23CUE0.26- - -0.58
2026-03-24CUE0.25- - -0.58
2026-03-25CUE0.26- - -0.58
2026-03-26CUE0.25- - -0.58
2026-03-27CUE0.24- - -0.58
2026-03-30CUE0.23- - -0.58
2026-03-31CUE0.23- - -0.58
2026-04-01CUE0.20- - -0.58
2026-04-02CUE0.18- - -0.58
2026-04-06CUE0.18- - -0.58
2026-04-07CUE0.19- - -0.58
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09CUE116.395.112.18
2026-03-10CUE116.395.112.18
2026-03-11CUE116.395.111.97
2026-03-12CUE116.405.111.97
2026-03-13CUE116.395.111.97
2026-03-18CUE116.375.111.97
2026-03-19CUE98.035.111.84
2026-03-20CUE98.015.111.84
2026-03-23CUE97.994.081.84
2026-03-24CUE97.994.081.84
2026-03-25CUE97.984.082.34
2026-03-26CUE98.034.082.34
2026-03-27CUE98.014.082.34
2026-03-30CUE98.004.082.34
2026-03-31CUE98.004.082.34
2026-04-01CUE98.014.082.34
2026-04-02CUE98.024.082.34
2026-04-06CUE97.994.082.34
2026-04-07CUE97.994.082.34
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.01

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

Insider Transactions

97.99

Institutional Transactions

4.08

Beta

1.58

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

24

Growth Score

37

Sentiment Score

12

Actual DrawDown %

99

Max Drawdown 5-Year %

-99

Target Price

4

P/E

Forward P/E

PEG

P/S

0.67

P/B

0.69

P/Free Cash Flow

EPS

-0.31

Average EPS Est. Cur. Y​

-0.58

EPS Next Y. (Est.)

-0.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-96.85

Relative Volume

51.32

Return on Equity vs Sector %

-128.1

Return on Equity vs Industry %

-111.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.11

EBIT Estimation

CUE Healthcare
$0.19
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
9/25
Volume
3/15
Valuation
12/20
TP/AR
2/10
Options
6/10
RSI
29.7
Range 1M
9.3%
Sup Dist
13%
🚀
Momentum Growth
Ride accelerating trends
N/A
29 /100
WEAK
Momentum
0/25
Growth
14/30
Estimates
0/20
Inst/Vol
7/15
Options
8/10
EPS Yr
-107.1%
EPS NY
-3.5%
52W%
2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +2005.3% upside
Quality
6/30
Valuation
16/30
Growth
8/25
Stability
7/10
LT Trend
1/5
Upside
+2005.3%
Quality
24
Cue Biopharma, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 29
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
CUE

Latest News

Caricamento notizie per CUE
stock quote shares CUE – Cue Biopharma Inc Stock Price stock today
news today CUE – Cue Biopharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CUE – Cue Biopharma Inc yahoo finance google finance
stock history CUE – Cue Biopharma Inc invest stock market
stock prices CUE premarket after hours
ticker CUE fair value insiders trading